Appointment of David Scadden, M.D. and Marella Thorell Resignation of Regina Hodits and Björn Odlander PHILADELPHIA , July 1, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carism...
Development Candidate targets Glypican-3 for the treatment of solid tumors, including hepatocellular carcinoma Nomination triggers a $2 million milestone payment to Carisma PHILADELPHIA , June 27, 202...
PHILADELPHIA , June 25, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing in...
Fast Track designation highlights potential for CT-0525 to address unmet need for patients with solid tumors Initial Phase 1 data expected by year-end 2024 PHILADELPHIA , June 25, 2024 /PRNewswire/ --...
Meeting will be reconvened on Friday, June 14, 2024 at 10:00 a.m. Eastern Time PHILADELPHIA , June 13, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a c...
PHILADELPHIA , May 30, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing inn...
CT-0525 is the first CAR-Monocyte to be evaluated in humans in the solid tumor setting Initial data expected by year-end 2024 PHILADELPHIA , May 16, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Na...
Carisma Therapeutics Inc. (CARM) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $1.93 per share a year ago....
Announced CT-0525 as lead product candidate for anti-HER2 program; initial data expected by year-end 2024 Presented preclinical proof of concept data in liver fibrosis at ASGCT; expects to nominate a ...
Novel anti-fibrotic engineered macrophage therapy reduced liver fibrosis in preclinical models Development candidate nomination expected in the first quarter of 2025 PHILADELPHIA , May 8, 2024 /PRNews...
PHILADELPHIA , May 6, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing inno...